Sufentanil sublingual tablet system in the treatment of acute postoperative pain in adults: a profile of its use

Sufentanil sublingual tablet system in the treatment of acute postoperative pain in adults: a... The novel sufentanil sublingual tablet system (sufentanil STS; Zalviso®) provides an alternative option to opioid-based intravenous patient-controlled analgesia (IV PCA) for the management of acute moderate to severe postoperative pain in adults in the hospital setting. It overcomes some of the drawbacks associated with opioid-based IV PCA, as the preprogrammed, noninvasive design of the sufentanil STS avoids the risk of pump programming errors and other complications that can occur with IV PCA technology. With each device activation, the patient-controlled sufentanil STS device delivers a sublingual sufentanil 15 μg nanotablet, with patients self-administering to analgesia by varying the interval between doses (minimum between-dose interval 20 min; maximum recommended treatment duration 72 h). Relative to morphine IV PCA, sufentanil delivered by the STS is as effective in relieving post-operative pain with a more rapid onset of analgesia and, according to patient and healthcare professional assessments, provides higher rates of success and overall satisfaction, and is easier to use. Sublingual sufentanil is generally well tolerated, with an adverse event profile typical of that of other opioids and a relatively low risk of respiratory depression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs & Therapy Perspectives Springer Journals

Sufentanil sublingual tablet system in the treatment of acute postoperative pain in adults: a profile of its use

Loading next page...
 
/lp/springer_journal/sufentanil-sublingual-tablet-system-in-the-treatment-of-acute-BTLn7vr6WQ
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Pharmacy; Pharmacy; Pharmacotherapy
ISSN
1172-0360
eISSN
1179-1977
D.O.I.
10.1007/s40267-017-0434-6
Publisher site
See Article on Publisher Site

Abstract

The novel sufentanil sublingual tablet system (sufentanil STS; Zalviso®) provides an alternative option to opioid-based intravenous patient-controlled analgesia (IV PCA) for the management of acute moderate to severe postoperative pain in adults in the hospital setting. It overcomes some of the drawbacks associated with opioid-based IV PCA, as the preprogrammed, noninvasive design of the sufentanil STS avoids the risk of pump programming errors and other complications that can occur with IV PCA technology. With each device activation, the patient-controlled sufentanil STS device delivers a sublingual sufentanil 15 μg nanotablet, with patients self-administering to analgesia by varying the interval between doses (minimum between-dose interval 20 min; maximum recommended treatment duration 72 h). Relative to morphine IV PCA, sufentanil delivered by the STS is as effective in relieving post-operative pain with a more rapid onset of analgesia and, according to patient and healthcare professional assessments, provides higher rates of success and overall satisfaction, and is easier to use. Sublingual sufentanil is generally well tolerated, with an adverse event profile typical of that of other opioids and a relatively low risk of respiratory depression.

Journal

Drugs & Therapy PerspectivesSpringer Journals

Published: Jul 31, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off